Watchmaker Genomics showcased inhibitor-tolerant Stellar RT-qPCR and qPCR kits alongside recombinase polymerase amplification enzymes at ESCMID Global, aiming at improved robustness in infectious disease workflows. The company’s focus is on assay performance in real clinical samples, where inhibitors and variable specimen quality can complicate traditional PCR. By highlighting inhibitor tolerance, Watchmaker’s product strategy targets repeatability and signal reliability—key requirements for clinical labs deciding whether to adopt new molecular methods for pathogen detection. The presentation also signals continued commercialization effort beyond platform development. If uptake follows, the tools could broaden the clinical utility of rapid molecular testing approaches, particularly in settings where sample variability drives false negatives or inconclusive results.